First Hawaiian Bank Purchases 2,329 Shares of Cencora, Inc. (NYSE:COR)

First Hawaiian Bank lifted its holdings in Cencora, Inc. (NYSE:COR - Free Report) by 21.9% in the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 12,983 shares of the company's stock after buying an additional 2,329 shares during the period. First Hawaiian Bank's holdings in Cencora were worth $3,610,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also modified their holdings of the business. JFS Wealth Advisors LLC boosted its position in Cencora by 63.0% during the fourth quarter. JFS Wealth Advisors LLC now owns 119 shares of the company's stock valued at $27,000 after purchasing an additional 46 shares during the last quarter. Banque Transatlantique SA acquired a new stake in Cencora during the fourth quarter valued at $29,000. SBI Securities Co. Ltd. acquired a new stake in Cencora during the fourth quarter valued at $30,000. Kentucky Trust Co acquired a new stake in Cencora during the fourth quarter valued at $33,000. Finally, WASHINGTON TRUST Co boosted its position in Cencora by 37.7% during the fourth quarter. WASHINGTON TRUST Co now owns 168 shares of the company's stock valued at $38,000 after purchasing an additional 46 shares during the last quarter. Institutional investors and hedge funds own 97.52% of the company's stock.

Insider Buying and Selling

In related news, EVP Elizabeth S. Campbell sold 4,127 shares of the business's stock in a transaction dated Monday, March 24th. The stock was sold at an average price of $268.28, for a total transaction of $1,107,191.56. Following the transaction, the executive vice president now directly owns 14,665 shares in the company, valued at $3,934,326.20. The trade was a 21.96% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, CAO Lazarus Krikorian sold 2,000 shares of the business's stock in a transaction dated Monday, March 10th. The shares were sold at an average price of $260.06, for a total value of $520,120.00. Following the transaction, the chief accounting officer now owns 20,154 shares in the company, valued at $5,241,249.24. This represents a 9.03% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders sold 45,223 shares of company stock valued at $12,369,767. Insiders own 10.80% of the company's stock.

Cencora Stock Up 0.3%

Shares of NYSE:COR traded up $0.80 on Friday, reaching $291.49. The company had a trading volume of 3,890,003 shares, compared to its average volume of 1,547,026. Cencora, Inc. has a twelve month low of $218.65 and a twelve month high of $309.35. The company has a quick ratio of 0.54, a current ratio of 0.92 and a debt-to-equity ratio of 16.40. The stock has a market capitalization of $56.50 billion, a P/E ratio of 41.46, a P/E/G ratio of 1.31 and a beta of 0.60. The stock has a 50-day moving average price of $284.83 and a 200 day moving average price of $258.55.

Cencora (NYSE:COR - Get Free Report) last posted its quarterly earnings data on Wednesday, May 7th. The company reported $4.42 earnings per share for the quarter, topping the consensus estimate of $4.07 by $0.35. Cencora had a return on equity of 328.62% and a net margin of 0.46%. The business had revenue of $75.50 billion during the quarter, compared to analysts' expectations of $75.41 billion. During the same quarter in the previous year, the firm earned $3.80 EPS. The firm's revenue was up 10.3% compared to the same quarter last year. On average, equities analysts expect that Cencora, Inc. will post 15.37 EPS for the current year.

Cencora Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, June 2nd. Investors of record on Friday, May 16th will be given a dividend of $0.55 per share. The ex-dividend date is Friday, May 16th. This represents a $2.20 annualized dividend and a dividend yield of 0.75%. Cencora's dividend payout ratio is presently 25.52%.

Wall Street Analyst Weigh In

COR has been the subject of a number of research reports. Morgan Stanley set a $288.00 price objective on Cencora in a research report on Tuesday, April 15th. Wall Street Zen raised Cencora from a "hold" rating to a "buy" rating in a research report on Wednesday, March 12th. Robert W. Baird lifted their price objective on Cencora from $314.00 to $350.00 and gave the company an "outperform" rating in a research report on Thursday, May 8th. Wells Fargo & Company boosted their price target on Cencora from $251.00 to $274.00 and gave the stock an "equal weight" rating in a research report on Friday, March 14th. Finally, Bank of America boosted their price target on Cencora from $270.00 to $285.00 and gave the stock a "neutral" rating in a research report on Friday, April 11th. Two equities research analysts have rated the stock with a hold rating and nine have given a buy rating to the stock. Based on data from MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus target price of $301.18.

About Cencora

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.